Cover Image
市場調查報告書

肝細胞生長因子 (Hepatopoietin-A,Lung Fibroblast Derived Mitogen) :開發中產品分析

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363117
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
肝細胞生長因子 (Hepatopoietin-A,Lung Fibroblast Derived Mitogen) :開發中產品分析 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 66 Pages
簡介

本報告提供肝細胞生長因子 (Hepatopoietin-A,Lung Fibroblast Derived Mitogen)的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Amgen Inc.
  • AnGes MG, Inc.
  • Kringle Pharma, Inc.
  • M3 Biotechnology, Inc.
  • Minerva Biotechnologies Corporation
  • Molecular Partners AG
  • ViroMed Co., Ltd.
  • Yooyoung Pharmaceutical Co., Ltd.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1015TDB

Summary:

According to the recently published report 'Hepatocyte Growth Factor - Pipeline Review, H2 2017'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.

The report 'Hepatocyte Growth Factor - Pipeline Review, H2 2017' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Hematological Disorders, Immunology and Metabolic Disorders which include indications Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Non-Small Cell Lung Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Angina (Angina Pectoris), Arteriosclerosis, Chronic Heart Failure, Colorectal Cancer, Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lymphedema, Metastatic Cancer, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Myocardial Ischemia, Parkinson's Disease, Rheumatoid Arthritis, Solid Tumor and Thromboangiitis obliterans (Buerger disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
    • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
    • AnGes MG Inc
    • F-star Biotechnology Ltd
    • Kringle Pharma Inc
    • M3 Biotechnology Inc
    • Minerva Biotechnologies Corp
    • Molecular Partners AG
    • ViroMed Co Ltd
    • Yooyoung Pharm Co Ltd
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate HGF for Myocardial Infarction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MM-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-0250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NDX-1017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NK-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-186 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-188 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YYB-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 03, 2017: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers
      • Apr 13, 2017: Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials
      • Apr 13, 2017: Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials
      • Feb 09, 2017: VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS)
      • Sep 20, 2016: F-star to present data on FS-101 at Upcoming AACR Conferences
      • Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy
      • Aug 02, 2016: VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease
      • Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy
      • Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia
      • May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis
      • Apr 15, 2016: AnGes Completes Patient Enrollment for Phase 1/2 Clinical Trials of Gene Therapy with HGF Plasmid in Primary Lymphedema
      • Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study
      • Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma
      • Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer
      • Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AnGes MG Inc, H2 2017
  • Pipeline by F-star Biotechnology Ltd, H2 2017
  • Pipeline by Kringle Pharma Inc, H2 2017
  • Pipeline by M3 Biotechnology Inc, H2 2017
  • Pipeline by Minerva Biotechnologies Corp, H2 2017
  • Pipeline by Molecular Partners AG, H2 2017
  • Pipeline by ViroMed Co Ltd, H2 2017
  • Pipeline by Yooyoung Pharm Co Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top